New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

Research output: Contribution to journalArticle

Abstract

To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)27-29
Number of pages3
JournalSeminars in Oncology
Volume28
Issue number2 SUPPL. 4
StatePublished - 2001

Fingerprint

Small Cell Lung Carcinoma
irinotecan
docetaxel
gemcitabine
Drug Therapy
Pharmaceutical Preparations
Topotecan
Survival
Leukopenia
Paclitaxel
Combination Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. / Ettinger, David S.

In: Seminars in Oncology, Vol. 28, No. 2 SUPPL. 4, 2001, p. 27-29.

Research output: Contribution to journalArticle

@article{90a09e1097f14ae4a1def91f68040f1d,
title = "New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer",
abstract = "To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27{\%} to 79{\%}. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.",
author = "Ettinger, {David S}",
year = "2001",
language = "English (US)",
volume = "28",
pages = "27--29",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

AU - Ettinger, David S

PY - 2001

Y1 - 2001

N2 - To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.

AB - To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034909054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909054&partnerID=8YFLogxK

M3 - Article

C2 - 11479894

AN - SCOPUS:0034909054

VL - 28

SP - 27

EP - 29

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -